272 related articles for article (PubMed ID: 31871140)
1. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.
Houssiau FA; Thanou A; Mazur M; Ramiterre E; Gomez Mora DA; Misterska-Skora M; Perich-Campos RA; Smakotina SA; Cerpa Cruz S; Louzir B; Croughs T; Tee ML
Ann Rheum Dis; 2020 Mar; 79(3):347-355. PubMed ID: 31871140
[TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
[TBL] [Abstract][Full Text] [Related]
4. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
[TBL] [Abstract][Full Text] [Related]
5. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
7. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
[TBL] [Abstract][Full Text] [Related]
8. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR
Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683
[TBL] [Abstract][Full Text] [Related]
9. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
[TBL] [Abstract][Full Text] [Related]
10. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
11. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
12. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
13. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
16. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Isenberg DA; Petri M; Kalunian K; Tanaka Y; Urowitz MB; Hoffman RW; Morgan-Cox M; Iikuni N; Silk M; Wallace DJ
Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
[TBL] [Abstract][Full Text] [Related]
18. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Wallace DJ; Kalunian K; Petri MA; Strand V; Houssiau FA; Pike M; Kilgallen B; Bongardt S; Barry A; Kelley L; Gordon C
Ann Rheum Dis; 2014 Jan; 73(1):183-90. PubMed ID: 23313811
[TBL] [Abstract][Full Text] [Related]
20. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]